My primary focus is to develop and execute biomarker strategies to support clinical development across the portfolio. This is pursued through research aimed at understanding both drug mechanism of action as well as disease pathophysiology.
After completing my postdoc at the University of California at San Francisco, I joined Celera Genomics and led the Chemical Proteomics group responsible for developing small molecule activity-based probes to study enzymes in their natural biological environment and to develop these probes as biomarkers of target engagement in the clinic. In 2006, I joined KAI Pharmaceuticals and championed preclinical research that led to the discovery of etelcalcetide, an approved drug for secondary hyperparathyroidism (SHPT). Prior to joining Calico, I worked at Genentech leading translational medicine and biomarker development in the areas of cardio‐metabolism, antimicrobial, ophthalmology and wound healing.